[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas

A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas  image

A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas

HealthTree Podcast for Myelofibrosis
event Dec 02, 2024 01:00PM - Dec 03, 2024 01:30PM EST
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

In this podcast episode, we will discuss the exciting new Phase III SENTRY clinical trial, which is currently open for recruiting, with the lead investigator, Dr. John Mascarenhas.

Schedule & Agenda

The panelist Dalton Bean
Introductions
1:00 PM
Dalton Bean

Dalton introduces the agenda of the event and our featured speaker John Mascarenhas, MD

The panelist John Mascarenhas, MD
Discussion with Dr. John Mascarenhas
1:05 PM
John Mascarenhas, MD

Dr. John Mascarenhas talks about the SENTRY trial

Speakers & Moderators

The panelist Dalton Bean
Dalton Bean
Lehi, UT

Dalton joined HealthTree in 2024 as the CLL and MF Education Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Read Bio
The panelist John Mascarenhas, MD
John Mascarenhas, MD

John Mascarenhas, MD, is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Mascarenhas is the Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, directs the Adult Leukemia Program, and is a member of The Tisch Cancer Institute. His clinical and research focus centers around myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). Throughout his illustrative career, Dr. Mascarenhas has published over 275 papers, is the principal investigator for the National Cancer Institute sponsored Myeloproliferative Disease Research Consortium, and has served as principal investigator or study chair on numerous clinical trials geared toward innovative treatment approaches for MPNs and AML. Dr. Mascarenhas is widely recognized for his work in MPNs and is often invited to speak at conferences for his expertise in the field.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

newsletter icon

Get the latest thought leadership on your Myeloproliferative Neoplasm delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.